Roche AG has discontinued three HIV discovery programmes because it has determined that they were unlikely to yield products that would be sufficiently innovative compared with what is already on the market. The programmes include one non-nucleoside reverse-transcriptase inhibitor (NNRTI) and two CCR5s, one of which was a small molecule and the other an antibody. The NNRTi drug candidate was a small molecule.
